PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, the U.S. subsidiary of Dexcel Pharma, today announced that Douglas S. Boothe has been named Chief Executive Officer, effective January 1, 2024. Boothe is an industry veteran with extensive accomplishments in the specialty, generic and over-the-counter pharmaceuticals business..

新泽西州帕西帕尼——（商业新闻短讯）——Dexcel Pharma的美国子公司Edenbridge Pharmaceuticals今天宣布，自2024年1月1日起，Douglas S.Boothe被任命为首席执行官。Boothe是一位行业资深人士，在专业、仿制药和非处方药业务方面取得了广泛的成就。。

Boothe has expertise in general management, strategy, sales and marketing, product selection, supply chain and business development in both the U.S. and global arenas. Over the course of his career, Boothe has overseen many successful new product development projects, regulatory reviews and approvals, paragraph IV litigations and commercial launches.

Boothe在美国和全球领域拥有综合管理、战略、销售和营销、产品选择、供应链和业务发展方面的专业知识。在他的职业生涯中，布思监督了许多成功的新产品开发项目、监管审查和批准、第四段诉讼和商业发布。

He has also reinvigorated research and development, regulatory, compliance and supply chain platforms in his past roles..

在过去的工作中，他还振兴了研发、监管、合规和供应链平台。。

“I am delighted to welcome Doug to Edenbridge at this pivotal time for the company,” said Ilan Oren, Co-Chief Executive Officer of Dexcel Pharma. “Doug’s deep pharmaceuticals expertise and proven track record aligns well with our growth strategy, and will help drive our vision of creating a broad portfolio of limited source pharmaceutical products and providing high-quality, affordable and accessible alternatives in a large and very important healthcare market.”.

德克塞尔制药公司联合首席执行官伊兰·奥伦（IlanOren）表示：“在公司的这个关键时刻，我很高兴欢迎道格（Doug）来到伊登布里奇（Edenbridge）。”。“Doug深厚的制药专业知识和可靠的业绩记录与我们的增长战略非常吻合，并将有助于推动我们的愿景，即在一个庞大而非常重要的医疗保健市场中创建一个广泛的有限来源药品组合，并提供高质量、经济实惠且可获得的替代品。”。

Boothe said, “I am excited about the opportunity to lead Edenbridge Pharmaceuticals and to expand our U.S. footprint through product acquisition and development partnerships with a focus on quality, affordability and accessibility.”

Boothe说：“我很高兴有机会领导Edenbridge Pharmaceuticals，并通过产品收购和开发合作伙伴关系扩大我们在美国的足迹，重点是质量、可负担性和可及性。”

Booth will succeed Edenbridge President and Co-founder Patrick Chu, who will retire from the Company.

Booth将接替Edenbridge总裁兼联合创始人PatrickChu，后者将从公司退休。

Oren added, “On behalf of the entire Dexcel organization, I’d like to thank Patrick for his tremendous leadership and contributions in building Edenbridge and positioning the organization for success.”

Oren补充道：“我代表整个Dexcel组织，感谢Patrick在构建Edenbridge和定位组织取得成功方面的巨大领导和贡献。”

About Douglas S. Boothe

关于道格拉斯·S·布思

Most recently, Boothe served as the President and Chief Executive Officer of Akorn, Inc. Prior to that, he was President of the generics division of Impax Laboratories, which developed, manufactured and marketed bioequivalent pharmaceuticals and was acquired by Amneal Pharmaceuticals LLC in a reverse merger transaction in May 2018.

最近，Boothe担任Akorn，Inc.的总裁兼首席执行官。在此之前，他是Impax Laboratories仿制药部门的总裁，该部门开发，制造和销售生物等效药物，并于2018年5月在反向并购交易中被Amneal pharmaceuticals LLC收购。

Earlier roles include Executive Vice President and General Manager of Perrigo Company Plc, with responsibility for the approximately $1 billion U.S. pharmaceuticals business, which included generics and specialty pharmaceutical products. He also served as the CEO of Actavis Inc., the U.S. manufacturing and marketing division of Actavis Group, and held senior positions at Alpharma and Pharmacia Corp.

此前担任的职务包括Perrigo Company Plc的执行副总裁兼总经理，负责约10亿美元的美国制药业务，其中包括仿制药和特种药品。他还曾担任Actavis集团美国制造和营销部门Actavis Inc.的首席执行官，并在Alpharma和Pharmacia Corp.担任高级职位。

Boothe received his undergraduate degree from Princeton University and his MBA from the Wharton School of Business at the University of Pennsylvania..

Boothe在普林斯顿大学获得学士学位，在宾夕法尼亚大学沃顿商学院获得MBA学位。。

About Edenbridge

关于Edenbridge

Edenbridge Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and marketing prescription pharmaceutical products. Our goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable and accessible alternatives in the healthcare market.

Edenbridge Pharmaceuticals是一家专注于识别、开发和销售处方药产品的专业制药公司。我们的目标是创建一个广泛的有限来源品牌和仿制药产品组合，在医疗保健市场上提供高质量、经济实惠和可获得的替代品。

Our approach is to work with best-in-class and like-minded industry partners to deliver our products to physicians and patients everywhere..

我们的方法是与一流且志同道合的行业合作伙伴合作，将我们的产品交付给世界各地的医生和患者。。

Founded in 2008, we launched our first product in February 2010 and have sold our commercial products through every major channel of the U.S. prescription pharmaceutical supply chain. In addition, we have a robust product development pipeline that includes 505(b)(2) NDAs, ANDAs, and foreign filings..

我们成立于2008年，于2010年2月推出了第一款产品，并通过美国处方药供应链的每个主要渠道销售了我们的商业产品。此外，我们拥有强大的产品开发渠道，其中包括505（b）（2）NDA、ANDA和外国文件。。